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Background and Introduction
For decades, patients, doctors, ethicists, and other interested parties have debated
the economics of the pharmaceutical industry. What is the best way to get 
medications and related products to the people who need them, regardless 
of their ability to pay for these drugs? Can prices can be lowered without 
jeopardizing basic research for new drugs? Are pharmaceutical company pricing 
practices monopolistic? What are the legal and ethical obligations related to
drugs developed—partially or fully—with public funds? 
The Population Council convened a daylong 
meeting of an eminent group of academics, scientists,
representatives from the nonprofit sector, the pharma-
ceutical industry, foundations, and government donor
agencies, and practicing lawyers and doctors—all of
whom have some connection with pharmaceutical
products. The purpose of the Day of Dialogue 
was to explore ways of getting medicinal 
products—especially those invented and developed
partially or fully using public funding—into the 
hands of the poor people of the world, wherever 
they live.
Scherer’s analysis of profits from pharmaceutical sales
and investments in research and development (R&D)
showed that when profits increase, so does R&D. This
suggests that pharmaceutical companies engage in what
economists call “virtuous rent-seeking.” However, said
Scherer, there is still cause for concern. Most R&D is for
diseases prevalent in industrialized countries, not those
in developing countries. And, while profits themselves
drive R&D, the threat that a company will lose profits
(via patent expiration, for example) also drives R&D.
The percentage of prescriptions filled with generic ver-
sions of drugs whose patents have lapsed rose from 18
percent in 1980 to 48 percent in 2000. Another problem
is a tendency to develop “me too” drugs—modified
mimics of existing medications that are designed to
extend patent protection—rather than to develop drugs
to treat diseases that have few or no treatments available.
Pharmaceutical R&D is a risky business, with 
7 out of 10 new drug entities failing to recover their
R&D costs. To fill otherwise depleted new product
pipelines, the drug industry is relying to an increasing
extent on publicly financed researchers at universities
and nonprofit institutions, along with scientists at
biotech firms, to conduct much of the preclinical
research. Thus, drug companies’ preclinical outlays, as a
percentage of total discounted R&D outlays for new
drugs, have declined, from 61 percent in the 1970s to 42
percent in the 1990s.
Scherer argued—and many participants agreed—that
two types of entities are badly needed if drug prices are to
Economics of Pharmaceutical R&D and Pricing
The day opened with a presentation by F.M. Scherer, Emeritus Harvard
University John F. Kennedy School of Government professor and current 
lecturer at Princeton’s Woodrow Wilson School, on the economics of 
pharmaceutical research and development and product pricing. 
Big pharma may very well be interested in pairing
with nonprofits to bring medicines to the developing
world, but there are ethical issues that concern the indus-
try. For example, the University of Pennsylvania has just
launched a project on ethics and vaccines. People on the
industry side have said that they think there may be too
much risk in these ventures that is not handled by prop-
er informed consent. Similarly, Caplan was asked by a
pharmaceutical company about producing anti-malarial
drugs. The company was concerned not with pricing,
but with being accused of exploitatively experimenting
in the developing world. 
Potential partners of pharmaceutical companies—
nonprofits that would like to bring low-cost medications
to the developing world—must recognize and manage
these and other ethical problems of the industry. The
reputation of big pharma is bad in the U.S., worse in
Europe, and worst in the developing world. 
The poor image of the industry is the result of several
factors. Recent books by Marcia Angell, Jerome P.
Kassirer, Jerry Avorn, and others have demonized the
industry. Drug prices are skyrocketing. And as some 
consumers have purchased cheaper Canadian drugs, the
industry has launched a campaign, which Caplan termed
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be held in check and if a greater variety of medicines are
to be made available: first, companies that can manage
clinical trials (which are costly and complicated) for uni-
versities, nonprofit organizations, and biotech firms; sec-
ond, institutions—like Walter Reed Army Medical Center
or the National Institutes of Health (NIH)—that can con-
duct drug screening, which is currently a bottleneck.
Participants stressed that a vital, undeveloped resource is
the chemical libraries owned by large pharmaceutical com-
panies; some of these molecules have been screened already.
These libraries serve as the companies’ “life savings.”
However, many companies may be interested in licensing
these drugs for developing-country uses as a way of
improving the image of an industry that has been
embroiled in difficulties. Negotiation with individual
companies would be required to gain access to these
libraries. Public-private partnerships (PPPs), which team
for-profit pharmaceutical companies with nonprofit enti-
ties, may be an appropriate construct to bridge this gap.
However, one big stumbling block in developing
products to address developing-world diseases is the cost
of clinical trials. Continuous, reliable funding is needed.
The NIH previously provided this money, but is now
doing so less often. Large drug companies have shown
some willingness to pay for trials, but will not offer
much until the PPP model is proven.
One participant noted that in some countries there is
a “use it or lose it” patent policy. A change of this sort,
or a variation thereof, in U.S. patent law might be help-
ful in bringing promising but shelved compounds into
testing. Another participant pointed out that one of the
costliest and most time-consuming aspects of bringing
new drugs to market is the new drug application (NDA)
process. She asked whether drug companies should pur-
sue Food and Drug Administration (FDA) or European
Medicines Agency (EMEA) regulatory approval, or is
approval outside the United States and the European
Union acceptable?
Ethical Considerations in Public-Sector Pricing of Pharmaceutical Products
Arthur Caplan, chair of the University of Pennsylvania’s department of Medical
Ethics, explored the question, “Can ethics save pharma?” Caplan acknowledged
that NIH funding is limited and will remain so for a while. He stated that
those who seek innovation in drug availability and pricing will need to look to
the pharmaceutical companies. 
“ludicrous,” questioning the safety of Canadian drugs.
He said the issue is the reliability of middlemen, not the
safety of what is sold in Canadian drug stores. 
Revelations in 2004 and 2005 about a link between
antidepressants and suicide in children, harmful side
effects caused by Vioxx and other cox-2 inhibitor drugs,
and other disclosures have further damaged the reputa-
tion of the industry. A recent Harris Poll found that only
13 percent of Americans believe that the pharmaceutical
industry is “generally honest and trustworthy.” Its repu-
tation has plunged faster than those of the tobacco, oil,
and managed care industries.
“Pharma is a very tricky partner to partner with,” said
Caplan. “These ethics problems are going to get in the
way, no matter how easy it is to get the products on the
shelf.” He suggested several means of starting to dispell the
demons that haunt the industry. Big pharma could under-
take a public relations campaign and redouble its lobbying
efforts. The most effective action, however, would be dra-
matic changes in pharmaceutical industry culture. 
Drug companies could rededicate themselves to the sci-
entific foundations of the industry. They could register all
clinical trials. When testing a new drug to treat a condition
for which there are already existing medications, they could
conduct clinical trials that compare the new drug to the
best available treatment rather than to a placebo. 
The pharmaceutical industry could recommit itself to
receiving ethical guidance—from data safety monitoring
boards (DSMBs) and institutional review boards (IRBs),
among others—on how it does research, marketing, and
sales. (Drug companies should ensure that the composi-
tion of these groups reflects the public interest and pub-
lic good.)
The industry could stop its most criticized marketing
practices: direct-to-consumer (DTC) marketing and free
samples to physicians and patients. Some large drug com-
panies are already taking a step in this direction. On 13
June 2005, for instance, Bristol-Myers Squibb announced
that it will refrain from direct-to-consumer advertising for
a minimum of 12 months following the launch of any
new drug. It will also limit television advertising to
“appropriate audiences at appropriate times.” 
(One participant defended DTC marketing in some
cases. The ParaGard® T 380A IUD is a great product, he
stated, but IUDs have a bad reputation in the U.S.
because of the Dalkon Shield tragedy. “How do we get the
word out to the public that this is a good product?” asked
the participant. DTC marketing is a promising approach.) 
Finally, some kind of assessment and accountability
should be built into the system. Johnson & Johnson, for
example, has set up its management structure so that
each drug in its portfolio has an “ethics manager.” This
policy sprang from concerns surrounding opioid medi-
cines, but it is a good way for any pharmaceutical com-
pany to ensure that greater attention is paid to ethical
obligations surrounding all drug developments. 
A participant inquired about the ethical obligations
that pharmaceutical companies have to their sharehold-
ers. How can a company defend its decision to share its
drug library, participate in a PPP, or contribute to other
ventures that do not increase profits but may help poor
people? Caplan replied that suits are possible but that
helping the poor sometimes is essential to doing business
in healthcare. He said companies in the healthcare sector
have particular duties to advance the public good that do
not encumber other industries. There is also a public
relations value to these activities; they help to de-demo-
nize the company and the industry. Finally, said Caplan,
pharmaceutical companies that conduct research in
developing countries are obligated to leave something
behind, though not necessarily the drug. Companies, for
example, can take steps to improve the local infrastruc-
ture. Local partners and citizens should be enlisted in
determining company obligations, and these promises
should be kept whether or not the product being tested
is found to be effective.
There are different moral dynamics surrounding the
testing of treatments for illnesses and the testing of prod-
ucts for healthy people that are meant to keep them
healthy, such as microbicides, contraceptives, and vaccines.
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The Bayh-Dole Act and Its Effect on the Availability of Products 
Developed with U.S. Public Funding
Howard Bremer, J.D., a consultant in patent, licensing, and technology 
transfers, is a widely acknowledged expert on the Bayh-Dole Act, which governs
the disposition of intellectual property resulting from research funded fully or
partially by the U.S. government. He presented information about the Act and
its effect on availability of products developed with U.S. public funding. 
For these types of products, there may be serious repercus-
sions if a clinical trial causes a single death. This may
come into play with tests of a rotavirus vaccine, for exam-
ple, which may begin in Africa and Asia by the end of
2006. Bioethics has not done a good job in addressing this
issue, contended Caplan.
Another participant pointed out that in addition to
ethical issues related to the development of molecules
and research in the field, drug companies need to invest
more in product introduction and post-marketing sur-
veillance. She asked whether there is a role for public-
sector organizations to do that. Caplan agreed that bad
post-marketing surveillance is an important ethical and
policy problem. Registering trials should be a condition
of working with journals, academic medical centers, uni-
versities, and governments. There should be consensus
on ethical trial design, and all outcomes of all trials—not
just those for drugs that are eventually approved or mar-
keted—should be electronically searchable and accessi-
ble. Participants agreed that negative results from trials
have to be made available, whether published in a jour-
nal, announced in a news release, or publicized in other
ways. Companies and public health both suffer in the
long run if adverse findings are or seem to be hidden.
Another participant raised the issue of differential
pricing. When research is based on public funds, he said,
there should be a different pricing structure, even when
the product is licensed to a for-profit pharmaceutical
company. Others concurred that there are serious ethical
issues related to the pricing of drugs. For example,
human papillomavirus (HPV) vaccines—which prevent
infection with the virus and, thus, also prevent cervical
cancer—are likely to be blockbusters in developed 
countries. They are also desperately needed in the 
developing world, but may not be widely available there
unless pricing barriers can be overcome. There is a tug of
war going on in drug pricing, stated one participant. 
The pharmaceutical industry and its investors want the
highest price possible and the public sector does not
want to pay anything. 
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Bayh-Dole is codified in 35 U.S.C. § 200-212 and is
implemented by 37 C.F.R. 401. Prior to the enactment of
the legislation in 1980, the United States government
retained intellectual property rights to any invention creat-
ed as a result of government-funded research, regardless of
the amount of government funding. This circumstance
contributed to the loss of a technological advantage that
the United States had previously held in the world. Because
organizations did not own the rights to their inventions,
they had no incentive to pursue them to commercializa-
tion. Government agencies that funded the research often
did not pursue the commercialization of the products
either. Accordingly, the number of patents issued each year
on technology that was the direct result of federally sup-
ported research declined steadily for several years prior to
the enactment of the law. As a result, products based on
government-funded research never reached the public.
Bayh-Dole was designed specifically to address this
roadblock. It allows universities, businesses, and 
nonprofits to retain rights to inventions they make or
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develop with federal funding. In exchange, these organi-
zations are required, among other things, to promote
and attempt to commercialize such inventions. At the
time the legislation was first proposed, there was some
criticism of it. Some senators opposed it on the basis that
“if the taxpayer funds the research, the taxpayer should
own the ideas produced.” However, in practice this
approach had led to a situation in which “the taxpayers
were getting no benefit whatsoever,” according to
Senator Birch Bayh, co-sponsor of the Act. 
As a safeguard against noncompliance with the
requirements of the Act, the government reserved
“march-in rights.” Under very specific circumstances—
for example, if the inventing organization does not
actively promote and attempt to commercialize its inven-
tion or if action is needed to protect the health and safe-
ty of consumers—these march-in rights require the
inventor to grant licenses for the invention to responsible
applicants, on terms that are reasonable under the cir-
cumstances. If the inventor refuses such a request, the
government is allowed to grant such licenses itself. 
Some observers have argued that the Bayh-Dole Act
states that inventions produced by government funding
must be made available to the public at a “reasonable
price.” However, this contention has been publicly refut-
ed by Senators Bayh and Robert Dole, the co-sponsors
of the legislation, and by experts in patent law, including
Bremer. In 2004, the National Institutes of Health was
petitioned to exercise march-in rights on the basis of the
cost of a drug (Norvir, a protease inhibitor used to treat
HIV infection). However, to date, no federal agency has
exercised these rights.
One participant asked about the mechanism for ethi-
cal oversight now that universities and other research
organizations stand to profit from their research. Bremer
answered that most universities have established conflict-
of-interest groups to alleviate perceived and real conflicts
of interest. The Bayh-Dole Act is supposed to ensure
that the public benefits from federally funded research.
The law, says Bremer, is as viable today as it was when it
was enacted. The essence of the law is being emulated
around the world: in Germany, Japan, and elsewhere. 
Regarding the march-in rights, one participant puz-
zled over the government’s interpretation of the wording
in Bayh-Dole. The law states that the government can
march in when “action is necessary to alleviate health or
safety needs which are not reasonably satisfied by the
contractor, assignee, or their licensees.” The participant
asked rhetorically whether health needs are being 
reasonably satisfied when the price of a drug is raised by
a factor of five (as happened with Norvir).
The government must be very careful, though, not to
exercise march-in rights hastily, noted another partici-
pant. Innovation would be discouraged if organizations
thought that patents would be taken away if they accept-
ed government funds. 
The exercise of march-in rights is not likely to be
undertaken to correct drug prices, argued another partic-
ipant. All administrations are pro-business and there is
no benefit for businesses in controlling private-sector
prices. We would like companies to do good and do
well. Companies should make some money—though 
little—in the public sector. They should not have to 
give their products away. If there is no profit, what is a
reasonable return for selling it in the public sector only?
What is a reasonable negotiation?
In answer to this, one participant stated his belief
that all licensing agreements should have some language
guaranteeing public-sector pricing. There must be 
some agreement at the outset that the price will be 
cost, plus a small amount. Some other participants
strongly disagreed that such an approach is feasible. 
One stated, “there are many factors that go into that
decision and to assume that it can be set at the outset 
is perhaps naïve.” Another noted that to have the terms
set at the outset might present some problems.
“Confidentiality. Deals change. I would offer as a 
consideration that it’s good to have an idea of where you
want to get but you have to understand the nature of
business agreements.”
Another participant concurred, stating that such a
simplistic approach carries the assumption that there is a
one-to-one ratio between patent and product. In fact,
treatments typically are based on a number of patents
often held by a variety of organizations. Adjuvants, drug
ingredients whose function is to facilitate or modify the
action of the principal ingredient, are cross licensed, for
example. Nonprofit institutions and universities do not
usually have the rights to all the pieces, or even the pri-
mary piece of a therapy. “We are committed to providing
low-cost drugs, but there are tons of constraints and our
negotiating position is weak.”
One participant gave the example of his institution’s
attempt to guarantee low prices for the public sector.
“We had in our collaborations reasonable pricing clauses
but we found that they drove away potential collabora-
tors,” he said. “It was more effective to drop that clause
and try to facilitate tiered royalty rates, or to put in lan-
guage for indigent access programs.”
In addition to providing drugs at low cost to people in
the developing world, some participants argued forcefully
for products to be made available to low-income people in
the United States, noting that the poor in the U.S. are
often overlooked. Other participants disagreed with this
point of view, saying that it would be unfair for the
wealthy U.S. to “throw their poor into the same basket” as
poverty-stricken people in the developing world. A heated
debate ensued and no consensus was reached.
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Alternative Models of Differential Pricing for Medicines
The final segment of the day featured a videotape of Patricia M. Danzon, Professor
of Health Care Systems and Insurance and Risk Management at the University of
Pennsylvania Wharton School, presenting a talk on differential drug pricing through
confidential rebates. Discussion of the video was moderated by Ernst R. Berndt,
Professor of Applied Economics at the Massachusetts Institute of Technology Sloan
School of Management and the National Bureau of Economic Research.
The question of differential pricing has emerged in
two contexts. One is making existing drugs, particularly
HIV/AIDS drugs, affordable and available in developing
countries. Additionally, in the U.S. there have been con-
cerns about “parallel trade,” the importation of drugs
from countries where prices are low to countries where
prices are high.
As mentioned earlier in the meeting, there is general
agreement that the prices paid in poorer countries
should be lower than the prices paid in richer countries
(although there is no consensus about what the appro-
priate differentials are or how to implement them).
However, there is less agreement as to what the differ-
ential pricing should be within and among industrial-
ized countries and where middle-income countries
would fit. Danzon’s presentation focused on an
innovative strategy for providing price differentials in
various settings.
Companies’ ability to provide differential prices has
been eroded  by two phenomena. First, parallel trade
and, second, extensive referencing by governments that
regulate their prices based on prices in other countries.
A study conducted by Danzon found that drug price dif-
ferentials relative to per capita income were roughly
appropriate within the industrialized or more affluent
countries, but for the two middle-income countries in
her study—Mexico and Chile—prices were out of line
relative to per capita income.
There are two currently discussed approaches to achiev-
ing differential pricing. One is a system of mandated dis-
counts calculated as a percentage off some benchmark
price (the EU Commission proposed a 75 percent dis-
count off the average OECD price, restricted to drugs
for treating certain diseases, such as HIV/AIDS, malaria,
and tuberculosis). The other approach is a markup, per-
haps 15 percent, based on marginal cost. But this raises
the question of which marginal cost. What if additional
production capacity is required, for example? 
There is no consensus on which approach is eco-
nomically appropriate and politically acceptable. And,
even if governments could agree, there is no guarantee
that companies would be willing to supply drugs at
these prices. This is the case in part because price dif-
ferentials would be visible and, thus, the threat of par-
allel trade and of external referencing would remain.
Furthermore, having a set of regulated prices would
establish certain benchmarks and discourage competi-
tion below those prices.
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M I R E N A ®: I M P R O V I N G  A C C E S S  T O  A N E W  P R O D U C T
Discussion arose among participants about ways to make Mirena® more accessible 
to women in developing countries and to poor women in the United States. 
Mirena is a levonorgestrel-releasingintrauterine system (IUS) that was
developed by Population Council biomedical
researchers with some government funding.
Mirena is licensed to Schering AG and mar-
keted in the United States by its subsidiary,
Berlex Inc. The IUS is registered as a contra-
ceptive in more than 100 countries and is
available on all continents; it was approved
for use in the United States in December
2000. It combines the best features of hor-
monal contraceptives and intrauterine
devices (IUDs), delivering the progestin levo-
norgestrel directly to the uterus and providing
highly effective contraception for up to 
five years. Mirena also reduces bleeding,
including the excessive menstrual bleeding
experienced by some women. One partici-
pant noted that this decrease in menstrual
bleeding greatly reduces the risk of anemia,
thus making Mirena doubly important in the
developing world.
In its licensing agreements the
Population Council arranged for the creation
of two independent foundations (Berlex cre-
ated the ARCH Foundation, operating solely
in the U.S., and Schering created the
International Contraceptive Access [ICA]
Foundation) to provide Mirena to low-income
women. In 2005, the ARCH Foundation pro-
vided more than 12,000 Mirena units to poor
women in the United States, and in 2006 it
will provide 13,000. Schering AG has allo-
cated approximately 150,000 Mirena units to
the ICA Foundation through 2006; approxi-
mately 37,000 of these are at no charge and
the remainder are at a very low price. The
Foundation has transferred 3,800 units to
public-sector agencies in Ecuador at no
cost, where it has also sponsored insertion
training and introductory studies. It is also in
the process of sponsoring training and stud-
ies with and transferring free units to agen-
cies in Nigeria, Kenya, and Indonesia. 
One participant contended that the foun-
dations are distributing only token numbers
of Mirena and are not meeting the need that
they are set up to provide. Another attendee
countered that these foundations are “prim-
ing the pump.” Since Mirena is a relatively
new product, the demand for it in the devel-
oping world is comparatively low. An informa-
tion campaign is needed to raise its profile.
Even in places where it is available, local-
level challenges may need to be addressed.
Local agencies, for example, may not want
to replace the Copper T 380A IUD (a popular
nonhormonal contraceptive product that was
also developed by the Population Council).
The health systems themselves may have
major problems with staffing, distribution
capacity, and other issues. One attendee
argued that these foundations provide a way
to learn about the issues, but ultimately may
not be the best mechanism for widespread
distribution to poor women. 
There was further debate about the cost
to manufacture Mirena. Although the current
cost to produce an individual unit of Mirena
was not discussed, one attendee expressed
his belief that it would be possible to manu-
facture the product for less than 10 dollars
per unit. Another participant noted other
costs associated with Mirena, among them
provider training, preinsertion pregnancy
tests, and insertion of the device. A third par-
ticipant said that in frustration her foundation
had considered developing a low-cost gener-
ic version of Mirena, but would prefer that
Mirena itself could be made more readily
available to poor women.
Danzon and her colleagues have proposed a system of
achieving differential prices by permitting and encourag-
ing confidential rebates. In this system, manufacturers
would sell their products to wholesalers who would then
distribute the drugs at a uniform price worldwide. The
manufacturers would negotiate rebates with the final
purchasers and these rebates would be paid conditional
on purchases being made. This is the same model that is
used in the U.S. in which HMO benefit managers nego-
tiate different discounts with manufacturers and those
rebates are made electronically. The manufacturers sell at
a uniform price but price differentials exist because of
these rebates.
With this system, price differences are not observable
to other people. Thus, manufacturers are able to give
lower prices to low-income countries, knowing that
those prices will not spill over to the high-income coun-
tries. That ability to segment markets is assured because
parallel trade and external referencing are not possible.
This system is flexible across drugs and countries. It also
encourages competition.
The primary objection to the idea of confidential
rebates is that developing countries lack the bargaining
power to negotiate them. However, Danzon suggested
that third parties (e.g. nongovernmental organizations
or governments) bargain on behalf of consumers in
low-income countries and that part of this bargaining
could include price-volume contracts. In this sort of
system, if demand is really price sensitive, it is in the
interest of manufacturers to give deep discounts, pro-
vided that those discounts do not then spill over to
high-income markets. 
A second objection to this sort of system is that if
prices are not observable, then the system is open to cor-
ruption. This is particularly a concern where subsidies
from various government agencies might be involved.
This concern, however, can be addressed by arranging
for audits by a third party and the discounted prices
would not be observable to governments in other coun-
tries. This proposal applies equally well to price differ-
ences within the industrial world where there are real dif-
ferences in income.
One participant commented that “loose lips” could
sink the confidential rebate system by allowing for par-
allel trade. Other attendees suggested additional innova-
tive approaches. They acknowledged that a challenge
that needs to be addressed is that U.S. law stipulates
that the government gets the lowest offered price.
Genzyme circumvents this issue by either charging full
price for its drugs or giving them away. Another partici-
pant proposed that pharmaceutical companies should
have to decide in advance whether they are going to sell
their products in the developed or the developing world.
If they are going to sell in the developed countries, they
would lose all patent protection in the developing coun-
tries, and this would allow for the manufacture of inex-
pensive, generic versions of the drugs. Another partici-
pant suggested that a way to encourage companies to
work on treatments for tropical diseases would be for
foundations or governments to make advance purchase
commitments.
In its licensing agreements, the Population Council
arranged for the creation of two foundations to provide
its Mirena® intrauterine contraceptive system to low-
income women. Under its Mirena contract, Berlex Inc.,
established the not-for-profit ARCH Foundation to
assist low-income women in the United States who do
not have insurance coverage for Mirena. Schering AG
and its Finnish subsidiary, Schering Oy—the manufac-
turers of Mirena and its marketers outside the United
States—have established the International Contraceptive
Access (ICA) Foundation, which provides Mirena at
reduced prices to selected public-sector organizations in
order to help serve the needs of poor women and 
families, primarily in developing countries. The ICA
Foundation is the first foundation for the specific 
purpose of supplying products at reduced prices interna-
tionally. Controversy over the availability and cost of
Mirena in the developing world prompted a spirited




It is possible to draw several conclusions from the day’s discussion about the
public-sector pricing of pharmaceutical products and the work that remains to
be done. Among them:
1. Big pharmaceutical companies possess chemical
libraries that may include compounds that could be
useful. (Several organizations in attendance are bene-
ficiaries of donations of rights to such compounds.)
2. Intermittent funding does not enable organizations
to pursue drug development; new approaches and
mechanisms are needed to assure consistent funding.
3. Clinical trials conducted in developing countries
need to benefit the local population; something
must be left behind, such as health infrastructure
improvement, if not a drug. 
4. The cost associated with taking a pharmaceutical
product from the point at which a publicly funded
organization would license it to a pharmaceutical
company to its market introduction is many times
larger than and far outweighs the cost and public
funding preceding licensing.
5. Pharmaceuticals are not widgets. Companies in this
industry have a greater societal responsibility than
companies in other industries.
6. A major task is to find appropriate ways for donors
to subsidize important pharmaceutical products for
those unable to afford them.
7. License agreements from publicly supported research
organizations can include reasonable pricing clauses,
tiered royalty rates, and indigent access programs.
8. Funding of liability protection for not-for-profit
research entities is a significant concern that needs to
be addressed with donor organizations.
9. As is the case with funding for development, fund-
ing for commodity purchase must be consistent and
long-term in order for pharmaceutical companies to
commit the resources needed to supply the public
sector; advance purchase commitments provide a
mechanism.
10. Getting new products to the dock at a low price in a
developing country does not solve the problem.
Product introduction, adequate distribution chan-
nels, and infrastructure for delivery are also required.
Attending to these issues requires time and money.
Sandra P. Arnold
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